817 related articles for article (PubMed ID: 32135117)
1. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
Ruess DA; Görgülü K; Wörmann SM; Algül H
Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
[TBL] [Abstract][Full Text] [Related]
5. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
[TBL] [Abstract][Full Text] [Related]
6. Novel Therapeutics for Pancreatic Adenocarcinoma.
Lowery MA; O'Reilly EM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
[TBL] [Abstract][Full Text] [Related]
7. Stromal biology and therapy in pancreatic cancer: a changing paradigm.
Neesse A; Algül H; Tuveson DA; Gress TM
Gut; 2015 Sep; 64(9):1476-84. PubMed ID: 25994217
[TBL] [Abstract][Full Text] [Related]
8. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease.
Gromisch C; Qadan M; Machado MA; Liu K; Colson Y; Grinstaff MW
Cancer Res; 2020 Aug; 80(16):3179-3192. PubMed ID: 32220831
[TBL] [Abstract][Full Text] [Related]
10. Next-generation therapies for pancreatic cancer.
Buckley CW; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2024; 18(1-3):55-72. PubMed ID: 38415709
[TBL] [Abstract][Full Text] [Related]
11. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
12. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
13. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
14. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal.
Yu S; Zhang C; Xie KP
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188461. PubMed ID: 33157162
[TBL] [Abstract][Full Text] [Related]
16. PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma.
Chapin WJ; Reiss KA
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
[TBL] [Abstract][Full Text] [Related]
17. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
Singh RR; O'Reilly EM
Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
[TBL] [Abstract][Full Text] [Related]
18. Changing the course of pancreatic cancer--Focus on recent translational advances.
Javle M; Golan T; Maitra A
Cancer Treat Rev; 2016 Mar; 44():17-25. PubMed ID: 26924195
[TBL] [Abstract][Full Text] [Related]
19. Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas.
Giry-Laterriere M; Pinho AV; Eling N; Chantrill L; Rooman I
Curr Cancer Drug Targets; 2015; 15(6):463-8. PubMed ID: 26282546
[TBL] [Abstract][Full Text] [Related]
20. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
Riazy M; Kalloger SE; Sheffield BS; Peixoto RD; Li-Chang HH; Scudamore CH; Renouf DJ; Schaeffer DF
Mod Pathol; 2015 Oct; 28(10):1383-9. PubMed ID: 26226846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]